Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study
Jürgen Geisler(Oslo University Hospital), Sophie Yammeni(Aalborg University Hospital), Minna Jääskeläinen(Lapland Central Hospital), Cathrine Bergquist Fosskaug(Akershus University Hospital), Alina Carmen Porojnicu(Norwegian Cancer Society), Oskar T. Johannsson(Lapland Central Hospital), Peeter Karihtala(University of Helsinki), Anders Bonde Jensen(Aarhus University Hospital), Anna Thulin(Sahlgrenska University Hospital), Katri S. Selander(Oulu University Hospital), Ulrik Narbe(Lund University), Leena Tiainen(Tampere University Hospital), Barbro Holm(Novartis (Sweden)), Barbro Linderholm(Karolinska University Hospital), Henrik Lindman(Uppsala University), Erik Jakobsen(Aarhus University Hospital), Torgunn Kursetgjerde(Sahlgrenska University Hospital), Antonios Valachis(Örebro University Hospital), Jenny Bergqvist(Lund University), Malgorzata Tuxen(University of Copenhagen), Silje Songe-Møller(University Hospital of North Norway), Cecilia Ahlin(Akershus University Hospital), Eva Brix(Gentofte Hospital), Egil Støre Blix(University Hospital of North Norway), Anna Weder(Aalborg University Hospital), Ana Bosch Campos(Lund University), Ann Søegaard Knop(Copenhagen University Hospital), Bård Mannsåker(Nordland Hospital)
Cited by 6
Related Papers
Effect of Obesity on Prognosis After Early-Stage Breast Cancer
|Journal of Clinical Oncology|2010|600
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment
|PLoS ONE|2009|504
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
|Annals of Oncology|2022|461
Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer
|Journal of Clinical Oncology|2000|443